MultiGEN Diagnostics develops assays addressing the technical limitations in providing accurate comprehensive clinical information for better patient care. In doing so, MultiGEN has modified the “Gold Standard’ Sanger sequencing chemistry. Presently, MultiGEN has six modified chemistry platforms (MultiGEN™, Tumorplex™, PrimaCap™, IC-Code™, SeqVariant™ and DrugBind™). Based on combinations of these platforms, novel assays are developed in the areas of infectious diseases, oncology, pharmacogenomics, and drug development/personalized medicine.
MultiGEN Diagnostics envisions two avenues to bring these assays to the customers; By commissioning High Throughput Modules (HTMs) for laboratories that process more than 200 samples (mixture of different assays) per day; a single instrument for laboratories that process less than 200 samples mixture of different assays per day.
MultiGEN Diagnostics provides limited licensing opportunities to customers who may like to bring the assays in-house.